Valuation: BioCryst Pharmaceuticals, Inc.

Market Cap 2.52B 2.21B 2.04B 1.9B 3.57B 237B 3.64B 24.43B 9.46B 117B 9.45B 9.24B 407B P/E 2026 *
-4.13x
P/E 2027 * 34x
Enterprise Value 2.52B 2.21B 2.04B 1.9B 3.57B 237B 3.64B 24.43B 9.46B 117B 9.45B 9.24B 407B EV / Sales 2026 *
3.75x
EV / Sales 2027 * 3.46x
Free-Float
94.36%
Yield 2026 *
-
Yield 2027 * -
12/06 BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment MT
12/06 BioCryst Pharmaceuticals Presents New Clinical Data and Real-World Evidence for HAE Portfolio at the European Academy of Allergy and Clinical Immunology Annual Meeting CI
27/05 BioCryst Pharmaceuticals Presents New HAE Data From ORLADEYO And Navenibart At The European Academy Of Allergy And Clinical Immunology Annual Meeting CI
13/05 BioCryst Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 01:40 PM
07/05 BioCryst Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 06, 2026
07/05 BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
06/05 BioCryst Pharmaceuticals Swings to Q1 Net Loss, Revenue Increases; 2026 Revenue Guidance Reiterated MT
06/05 Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 Net Loss $2.98 a Share, vs. FactSet Est of $0.04 EPS MT
06/05 Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q1 Revenue $156.4M, vs. FactSet Est of $151.1M MT
06/05 BioCryst Pharmaceuticals, Inc. Maintains Earnings Guidance for the Full Year 2026 CI
04/05 BioCryst Pharmaceuticals Enters Licensing Deal for Navenibart With Neopharmed Gentili Affiliate MT
04/05 BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema CI
22/04 Tenax Therapeutics Names Thomas Staab as Chief Financial Officer MT
1 day-1.00%
1 week+10.12%
Current month+11.11%
1 month+19.42%
3 months+5.32%
6 months+28.57%
Current year+26.92%
1 week 8.91
Extreme 8.91
10.94
1 month 8.06
Extreme 8.06
10.94
Current year 6.23
Extreme 6.23
10.94
1 year 6
Extreme 6
10.94
3 years 4.03
Extreme 4.03
11.31
5 years 4.03
Extreme 4.03
19.99
10 years 1.38
Extreme 1.38
19.99
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2026
Director of Finance/CFO 47 07/07/2025
Chief Tech/Sci/R&D Officer 51 06/04/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2007
Director/Board Member 64 03/12/2018
Director/Board Member 55 01/01/2026
Date Insider Type Main position Quantity % Market Cap.
11/06Free

Director

48,834 0.0192%
11/06Free

Director

48,834 0.0192%
11/06Free

Director

48,834 0.0192%
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%+10.12%+1.64%+41.23% 2.54B
+4.43%+2.49%+61.83%+115.25% 52.88B
+1.58%+14.12%+72.87%+85.18% 50.98B
-0.23%-0.98%-14.12%-16.00% 22.81B
+0.98%+9.05%-0.36%+423.40% 22.43B
-0.54%+7.09%+31.68%-14.38% 17.01B
+0.88%+5.78%+30.82%-34.26% 15.91B
+3.02%+12.74%+143.33%+308.04% 13.58B
+0.68%+2.54%+22.28%+168.03% 13.29B
+0.39%+5.56%+27.45% - 12.56B
Average +1.02%+6.41%+37.74%+119.61% 22.4B
Weighted average by Cap. +1.74%+6.59%+45.87%+119.65%

Financials

2026 *2027 *
Net sales 671M 589M 543M 508M 952M 63.32B 970M 6.52B 2.52B 31.21B 2.52B 2.46B 108B 727M 639M 589M 550M 1.03B 68.62B 1.05B 7.06B 2.74B 33.83B 2.73B 2.67B 118B
Net income -674M -592M -545M -510M -956M -63.59B -974M -6.54B -2.53B -31.35B -2.53B -2.48B -109B 41.89M 36.8M 33.9M 31.7M 59.46M 3.95B 60.55M 407M 158M 1.95B 157M 154M 6.77B
Net Debt - -
Logo BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.
Employees
435
Date Price Change Volume
25/06/26 USD 9.900 -1.00% 19,059,610
24/06/26 USD 10.00 +7.41% 8,519,801
23/06/26 USD 9.310 +1.86% 5,144,624
22/06/26 USD 9.140 +1.67% 7,405,439
18/06/26 USD 8.990 +0.45% 8,882,726
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.900USD
Average target price
21.30USD
Spread / Average Target
+115.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCRX Stock